Synergism of Dimethoxybenzosemiquinone Free Radicals and CD4+ T-Lymphocytes to Suppress Ehrlich Ascites Tumor

Experimental Biology and Medicine

Volumn 217, Issue 1, 1998, Pages 89-96

  Morgan, Clinton D ^a,b   Lefkowitz, Stanley S ^a   Evers, Johannes ^a  

^a TEXAS TECH UNIVERSITY   (United States)

^b Scott White Mem Hosp and Clinics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FREE RADICAL; SEMIQUINONE;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CONFERENCE PAPER; CONTROLLED STUDY; EHRLICH ASCITES TUMOR; FEMALE; HELPER CELL; MALE; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, HETEROPHILE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ASCORBIC ACID; BENZOQUINONES; CARCINOMA, EHRLICH TUMOR; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; COMBINED MODALITY THERAPY; FEMALE; FREE RADICALS; LYMPHOCYTE DEPLETION; MALE; MICE; MICE, INBRED BALB C; RATS; T-LYMPHOCYTES;

ANIMALIA;

EID: 0031962482     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.3181/00379727-217-44209     Document Type: Article

References (40)

1. Brunmark A, Cadenas E. Redox and addition chemistry of quinoid compounds and its biological implications. Free Rad Biol Me 7:435-477, 1989.
2. Powis G. Metabolism and reactions of quinoid anticancer agents. Pharmacol The 35:57-162, 1987.
3. Gutierrez PL. Mechanism(s) of bioreductive activation: The example of diaziquinone (AZQ). Free Rad Biol Me 6:405-445, 1989.
4. Bachur NR, Gordon SL, Gee MV. A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Re 38:1745-1750, 1978.
5. Halliwell B, Gutteridge JM. Oxygen toxicity, oxygen radicals, transition metals, and disease. Biochem 219:1-14, 1984.
6. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H. Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol The 47:219-231, 1990.
7. Pethig R, Gascoyne PRC. McLaughlin JA, Szent-Gyorgyi A. Ascorbate-quinone interactions: Electrochemical, free radical, and cytotoxic properties. Proc Natl Acad Sci US 80:129-132, 1983.
8. Pethig R, Gascoyne PRC, McLaughlin JA, Szent-Gyorgyi A. Interaction of th 2,6-dimethoxysemiquinone and ascorbyl free radicals with Ehrlich ascites cells: A probe of surface cell charge. Proc Natl Acad Sci US 81:2088-2091, 1984.
9. Pethig R, Gascoyne PRC, McLaughlin JA, Szent-Gyorgyi A. Enzyme-controlled scavenging of ascorbyl an 2,6-dimethoxysemiquinone free radicals in Ehrlich ascites tumor cells. Proc Natl Acad Sci US 82:1439-1442, 1985.
10. Byrnes RW, Templin J, Sem D, Lyman S, Petering DH. Imracellular DNA strand scission and growth inhibition of Ehrlich ascites tumor cells by bleomycins. Cancer Re 50:5275-5286, 1990.
11. Fecchio D, Russo M, Sirois P, Braquet P, Jancar S. Inhibition of Ehrlich ascites tumor in viva by PAF-antagonists. Int J Immunopharmaco 12:57-65, 1990.
12. Friche E, Jensen PB, Roed H, Skovsgaard T, Nissen NI. In vitro circumvention of anthracydine-resistance in Ehrlich ascites tumor by anthracycline analogues. Biochem Pharmaco 39:1721-1726, 1990.
13. Friche E, Danks MK, Schmidt CA, Beck WT. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Cancer Re 51:4213-4218, 1991.
14. Sprent J, Schaffer M. Properties of purified T cell subsets. I. In vitro responses to class I vs. class II H-2 alloantigens. J Exp Me 162:2068-2088, 1985.
15. Hornbeck P. Enzyme-linked immunosorbent assays. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Stober W. Eds. Current Protocols in Immunology. New York: John Wiley & Sons, Vo 1: 2.1.2, 1991.
16. Morrow KJ, Unuvar E, King SW, Mleczko JB. Techniques for the production of monoclonal and polyclonal antibodies. In: Hayat MA, Ed. Colloidal Gold: Principles, Methods, and Applications. San Diego: Academic Press, Inc., Vo 3: 31, 1991.
17. Husmann LA, Bevan MJ. Cooperation between helper T cells and cytotoxic T lymphocyte precursors. In: Battisto JR, Plate J, Shearer G, Eds. Cytotoxic T Cells: Biology and Relevance to Disease. New York: The New York Academy of Sciences, Vo 532: 158, 1988.
18. Chou T, Shu S. Cellular interactions and the role of interleuki 2 in the expression and induction of immunity against a syngeneic murine sarcoma. J Immuno 139:2103-2109, 1987.
19. Gorozny J, Weyand CM, Fathman CG. Long-term humoral unresponsiveness in vivo induced by treatment with monoclonal antibody against L3T4. J Exp Me 164:911-925, 1986.
20. Pratesi G, Rodolfo M, Rovetta G, Parmiani G. Role of T cells and tumor necrosis factor in antitumor activity and toxicity of flavone acetic acid. Eur J Cance 26:1079-1083, 1990.
21. Sasaki DT, Dumas SE, Engleman EG. Discrimination of viable and non-viable cells using propidium iodide in two-color immunofluorescence. Cytometr 8:413-420, 1987.
22. Morgan CD, Combs SH, Everse J. Probable immune system mediation of the antitumor activity of th 2,6-dimethoxybenzo-p-semiquinone radical. Proc Soc Exp Biol Me 208:294-299, 1994.
23. Cummings J, Anderson L, Willmott N, Smyth JF. The molecular pharmacology of doxorubicin in vivo. Eur J Cance 27:532-535, 1991.
24. Doroshow JH, Akman S, Chu F-F, Esworth S. Role of the glutathione-glutathione peroxidase cycle in the cytotoxicity of the anticancer quinones. Pharmacol The 47:359-370, 1990.
25. Afanas'ev IB, Korkina LG, Suslova TB, Soodaeva SK. Are quinones producers or scavengers of superoxide ion in cells? Arch Biochem Biophy 281:245-250, 1990.
26. Ogura T, Shindo H, Namba M, Yamamura Y. Tumoricidal activity of peritoneal exudate cells from rats treated with mitomycin C. Jpn J Cancer Re 71:920-921, 1980.
27. Stoychkov JN, Schultz RM, Chirigos MA, Pavlidis NA, Goldin A. Effects of adriamycin and cyclophosphamide treatment on induction of macrophage cytotoxic function in mice. Cancer Re 39:3014-3017, 1979.
28. Bourguet-Kondracki M-I, Longeon A, Morel E, Guyot M. Sesquiterpene quinones as immunomodulating agents. Int J Immunopharmaco 13:393-399, 1991.
29. Ehrke MJ, Ryoyama K, Cohen S. Cellular basis for adriamycin-induced augmentation of cell-mediated cytotoxicity in culture. Cancer Re 44:2497-2504, 1984.
30. Ehrke MJ, Maccubin D, Ryoyama K, Cohen SA, Mihich E. Correlation between adriamycin-induced augmentation of interleuki 2 production and cell-mediated cytotoxicity in mice. Cancer Re 46:54-60, 1986.
31. Haskill JS. Adriamycin-activated macrophages as tumor growth inhibitors. Cancer Re 41.-3852-3856, 1981.
32. Martin FA, Caignard A, Olsson O, Jeannin JF, Leclerc A. Tumoricidal effect of macrophages exposed to adriamycin in vivo or in vitro. Cancer Re 42:3851-3857, 1982.
33. Santoni A, Riccardi A, Sorci V, Herberman RB. Effects of adriamycin on the activity of mouse natural killer cells. J Immunol 1224:2329-2335, 1980.
34. Sensi M, Bergomi M, Formelli F, Parmiani G. Eradication of a disseminated mouse lymphoma b 1,3-bis(2-chloroethyl)-1-nitrosurea is immunologically mediated and accompanied by de novo generation of anti-tumor cytotoxicity. Int J Cance 46:1088-1094, 1990.
35. Bowlin TL, Prakash NJ, Edwards ML, Sjoerdsma A. Participation of T-lymphocytes in the curative effect of a novel synthetic polyamine analogue, N'-bis[3-(ethylamino)propyl]-1 7-heptanediamine, against L1210 leukemia in vivo. Cancer Re 51:62-66, 1991.
36. Sodhi A, Singh SM. Increased capacity of lymphocytes to lyse tumor cells in vitro and production of lymphotoxins after cisplatin treatment. Int J Immunopharmaco 10:753-761, 1988.
37. Sodhi A, Pai K, Singh RK, Singh SM. Activation of human NK cells and monocytes with cisplatin in vitro. Int J Immunopharmaco 12:893-898, 1990.
38. Sodhi A, Singh RK, Pai K. Activation of murine macrophages by tumor necrosis factor, interleukin-1, interferon-gamma and cisplatin. Immunol Let 26:45-50, 1990.
39. Bibby MC, Phillips RM, Double JA, Pratesi G. Anti-tumor activity of flavone acetic acid (NS 347512) in mice-influence of immune status. Br J Cance 63:57-62, 1991.
40. Damia G, Tagliabue G, Allavena P, D'Incalci M. Flavone acetic acid antitumor activity against a mouse pancreatic adenocarcinoma is mediated by natural killer cells. Cancer Immunol Immunothe 32:241-244, 1990.